The apolipoprotein B receptor (APOBR), primarily recognized as the low-density lipoprotein receptor (LDLR), plays a central role in lipid metabolism by mediating cellular uptake of LDL particles containing apolipoprotein B (ApoB). This receptor is critical for maintaining cholesterol homeostasis, as it binds ApoB on LDL, facilitating its endocytosis and subsequent degradation to regulate plasma cholesterol levels. Dysregulation of LDLR/APOBR function is closely linked to hypercholesterolemia and atherosclerosis, making it a key target in cardiovascular research. APOBR-specific antibodies are essential tools for studying receptor expression, localization, and interaction mechanisms. They are widely employed in immunoassays (e.g., Western blot, ELISA), immunohistochemistry, and flow cytometry to investigate LDLR-related pathologies or therapeutic interventions. Monoclonal antibodies targeting APOBR have also been explored for therapeutic applications, such as inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9)-mediated LDLR degradation to lower LDL cholesterol. Additionally, autoantibodies against ApoB-containing lipoproteins have been implicated in autoimmune-related cardiovascular diseases, highlighting their diagnostic and prognostic potential. Research on APOBR antibodies continues to advance insights into lipid disorders and precision therapies for atherosclerosis.